

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

HELSINN HEALTHCARE S.A. and)	
ROCHE PALO ALTO LLC,)	
)	
Plaintiffs,)	
)	
v.)	C.A. No. 13-688 (GMS)
)	CONSOLIDATED
AUROBINDO PHARMA LTD. and)	
AUROMEDICS PHARMA LLC,)	
)	
Defendants.)	
<hr/>		
HELSINN HEALTHCARE S.A. and ROCHE)	
PALO ALTO LLC,)	
)	
Plaintiffs,)	
)	
v.)	C.A. No. 14-427 (GMS)
)	(All Documents Filed in 13-688 (GMS))
CIPLA LTD. and CIPLA USA, INC.,)	
)	
Defendants.)	

**AMENDED COMPLAINT FOR PATENT INFRINGEMENT
AGAINST CIPLA LTD. AND CIPLA USA, INC.**

Plaintiffs Helsinn Healthcare S.A. (“Helsinn”) and Roche Palo Alto LLC (“Roche”) (collectively, “Plaintiffs”), for their Complaint against Defendants Cipla Ltd. and Cipla USA, Inc. (collectively, “Defendants”), hereby allege as follows:

THE PARTIES

1. Helsinn is a Swiss corporation having its principal place of business at Via Pian Scairolo, 9, CH-6912 Lugano-Pazzallo, Switzerland.
2. Roche is a company organized and existing under the laws of the State of Delaware, having a principal place of business at One DNA Way, South San Francisco, California 94080-4990.

3. Upon information and belief, Defendant Cipla Ltd. is a corporation organized under the laws of India, with its principal place of business at Mumbai Central, Mumbai – 400 008 India. Upon information and belief, Cipla Ltd., directly and/or through Cipla USA, Inc., markets, manufactures, distributes, and sells generic drugs for use in the State of Delaware and throughout the United States.

4. Upon information and belief, Cipla USA, Inc. is a corporation organized and existing under the laws of the State of Delaware with its principal place of business at 9100 S. Dadeland Blvd., Suite 1500, Miami, FL 33156. Upon information and belief, Cipla USA, Inc. manufactures, markets, and/or sells various generic drug products for sale and use in the State of Delaware and throughout the United States, including generic pharmaceutical drugs manufactured by Cipla Ltd. Upon information and belief, Cipla USA, Inc. is a wholly owned subsidiary of, and the United States agent, affiliate, and/or representative of, Cipla Ltd., and has submitted regulatory filings to the FDA on behalf of Cipla Ltd.

5. Upon information and belief, the acts of Cipla USA, Inc. complained of herein were done at the direction of, with the authorization of, and with the cooperation, assistance, and/or participation of Cipla Ltd.

NATURE OF THE ACTION

6. This is a civil action concerning the infringement United States Patent No. 8,598,219 (“the ’219 patent”) and United States Patent No. 8,729,094 (“the ’094 patent”). This action arises under the patent laws of the United States, 35 U.S.C. §§ 100 *et seq.*, and the Declaratory Judgment Act, 28 U.S.C. §§ 2201-02.

JURISDICTION AND VENUE

7. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a) and the Declaratory Judgment Act, 28 U.S.C. §§ 2201-02.

8. This Court may declare the rights and other legal relations of the parties pursuant to 28 U.S.C. §§ 2201-02 because this case is an actual controversy within the Court's jurisdiction.

9. Venue is proper in this Court as to each Defendant pursuant to 28 U.S.C. §§ 1391(b), (c), and/or (d) and 1400(b).

10. This Court has personal jurisdiction over Defendants by virtue of the fact that, *inter alia*, both defendants have committed, aided, abetted, contributed to, and/or participated in the commission of a tortious act of patent infringement that has led to foreseeable harm and injury to Plaintiffs. This Court has personal jurisdiction over Defendants for the additional reasons set forth below, and for other reasons that will be presented to the Court if such jurisdiction is challenged.

11. This Court has personal jurisdiction over Cipla Ltd. by virtue of the fact that, *inter alia*, it: (1) engages in persistent conduct within Delaware, with and through its agent Cipla USA, Inc., a Delaware Corporation, including, upon information and belief, the preparation and submission of ANDA No. 206396; (2) has purposely availed itself of the privilege of doing business in this Judicial District including through, *inter alia*, Cipla USA, Inc., a Delaware Corporation; (3) maintains systematic contacts with the State of Delaware, including the marketing, distribution, and/or sale of generic pharmaceutical drugs to Delaware residents; (4) has previously consented to this Court's jurisdiction and taken advantage of the rights and protections provided by this Court, including having asserted counterclaims in this jurisdiction; and (5) has consented to personal jurisdiction for purposes of this action.

12. This Court has personal jurisdiction over Cipla USA, Inc. by virtue of the fact that, *inter alia*, it: (1) is incorporated in Delaware; (2) engages in persistent conduct within Delaware, including, upon information and belief, the preparation and submission of ANDA No.

206396; (3) has purposely availed itself of the privilege of doing business in this Judicial District; (4) maintains systematic contacts with the State of Delaware, including the marketing, distribution, and/or sale of generic pharmaceutical drugs to Delaware residents; and (5) has consented to personal jurisdiction for purposes of this action.

THE PATENTS-IN-SUIT

13. On December 3, 2013, the '219 patent, titled "Liquid Pharmaceutical Formulations of Palonosetron," was duly and legally issued to Plaintiffs as assignees. A copy of the '219 patent is attached as Exhibit A.

14. On May 20, 2014 the '094 patent, titled "Liquid Pharmaceutical Formulations of Palonosetron," was duly and legally issued to Plaintiffs as assignees. A copy of the '094 patent is attached as Exhibit B.

15. Pursuant to 21 U.S.C. § 355(b)(1), the '219 and '094 patents have been listed in the United States Food and Drug Administration ("FDA") publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (also known as the "Orange Book") as covering Helsinn's Aloxi[®] brand palonosetron hydrochloride intravenous solutions.

ACTS GIVING RISE TO THIS ACTION

COUNT I – INFRINGEMENT OF THE '219 PATENT

16. Plaintiffs reallege paragraphs 1-15 as if fully set forth herein.

17. Upon information and belief, Defendants submitted ANDA No. 206396 to the FDA under § 505(j) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355(j)). ANDA No. 206396 seeks the FDA approval necessary to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of generic 0.25 mg / 5 mL palonosetron hydrochloride intravenous solutions prior to the expiration of the '219 patent. ANDA No. 206396 specifically seeks FDA approval to market a generic version of Helsinn's Aloxi[®]

brand 0.25 mg / 5 mL palonosetron hydrochloride intravenous solutions prior to the expiration of the '219 patent.

18. Upon information and belief, ANDA No. 206396 includes a certification under § 505(j)(2)(A)(vii)(IV) of the Federal Food, Drug and Cosmetic Act that the claims of the '219 patent are invalid, and that certain (but not all) of the claims are not infringed by ANDA No. 206396.

19. Defendants' submission to the FDA of ANDA No. 206396, including the § 505(j)(2)(A)(vii)(IV) allegations, constitutes infringement of the '219 patent under 35 U.S.C. § 271(e)(2)(A).

20. Cipla Ltd. and Cipla USA, Inc. are jointly and severally liable for any infringement of the '219 patent. This is because, upon information and belief, Cipla Ltd. and Cipla USA, Inc. actively and knowingly caused to be submitted, assisted with, participated in, contributed to, and/or directed the submission of ANDA No. 206396 and the § 505(j)(2)(A)(vii)(IV) allegations to the FDA.

21. Defendants' active and knowing participation in, contribution to, aiding, abetting, and/or inducement of the submission to the FDA of ANDA No. 206396 constitutes infringement of the '219 patent under 35 U.S.C. § 271(e)(2)(A).

22. Plaintiffs are entitled to a declaration that, if Defendants commercially manufacture, use, offer for sale, or sell their proposed generic versions of Helsinn's Aloxi[®] brand products within the United States, import their proposed generic versions of Helsinn's Aloxi[®] brand products into the United States, and/or induce or contribute to such conduct, Defendants will infringe the '219 patent under 35 U.S.C. § 271(a), (b), and/or (c).

23. Plaintiffs will be irreparably harmed by Defendants' infringing activities unless those activities are enjoined by this Court. Plaintiffs do not have an adequate remedy at law.

COUNT II – INFRINGEMENT OF THE '094 PATENT

24. Plaintiffs reallege paragraphs 1-23 as if fully set forth herein.

25. Upon information and belief, Defendants submitted ANDA No. 206396 to the FDA under § 505(j) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355(j)). ANDA No. 206396 seeks the FDA approval necessary to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of generic 0.25 mg / 5 mL palonosetron hydrochloride intravenous solutions prior to the expiration of the '094 patent. ANDA No. 206396 specifically seeks FDA approval to market a generic version of Helsinn's Aloxi[®] brand 0.25 mg / 5 mL palonosetron hydrochloride intravenous solutions prior to the expiration of the '094 patent.

26. The '094 patent had not been issued at the time Defendants made their § 505(j)(2)(A)(vii)(IV) certification regarding Plaintiffs' other Orange Book-listed patents.

27. The '094 patent shares the same expiration date as Plaintiffs' other Orange Book-listed patents. By seeking FDA approval of their ANDA No. 206396 prior to expiration of Plaintiffs' other Orange Book-listed patents, Defendants necessarily seek approval of that ANDA prior to expiration of the '094 patent.

28. Upon information and belief, Defendants are required by law to either amend their ANDA to contain a § 505(j)(2)(A)(vii)(IV) certification with respect to the '094 patent as well, or must relinquish their request that the FDA approve ANDA No. 206396 prior to the expiration of the '094 patent.

29. Defendants' submission to the FDA of ANDA No. 206396, seeking immediate approval without waiting for patent expiration, constitutes infringement of the '094 patent under 35 U.S.C. § 271(e)(2)(A).

30. Cipla Ltd. and Cipla USA, Inc. are jointly and severally liable for any infringement of the '094 patent. This is because, upon information and belief, Cipla Ltd. and Cipla USA, Inc. actively and knowingly caused to be submitted, assisted with, participated in, contributed to, and/or directed the submission of ANDA No. 206396 and the § 505(j)(2)(A)(vii)(IV) allegations to the FDA.

31. Defendants' active and knowing participation in, contribution to, aiding, abetting, and/or inducement of the submission to the FDA of ANDA No. 206396 constitutes infringement of the '094 patent under 35 U.S.C. § 271(e)(2)(A).

32. Plaintiffs are entitled to a declaration that, if Defendants commercially manufacture, use, offer for sale, or sell their proposed generic versions of Helsinn's Aloxi® brand products within the United States, import their proposed generic versions of Helsinn's Aloxi® brand products into the United States, and/or induce or contribute to such conduct, Defendants would infringe the '094 patent under 35 U.S.C. § 271(a), (b), and/or (c).

33. Plaintiffs will be irreparably harmed by Defendants' infringing activities unless those activities are enjoined by this Court. Plaintiffs do not have an adequate remedy at law.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs request that:

- A. Judgment be entered declaring that Defendants have infringed the '219 and '094 patents by submitting ANDA No. 206396;
- B. An Order be issued pursuant to 35 U.S.C. § 271(e)(4)(A) that the effective date of any approval of ANDA No. 206396 be a date that is not earlier than the expiration dates of the '219 and '094 patents, or any later expiration of exclusivity for either of these patents to which Plaintiffs are or become entitled;
- C. An Order be issued that Defendants, their officers, agents, servants, and employees, and those persons in active concert or participation with either of them, are preliminarily and permanently enjoined from commercially manufacturing, using, offering for sale, importing, or selling the proposed generic versions of Helsinn's Aloxi[®] brand products identified in this Complaint, and any other product that infringes or induces or contributes to the infringement of the '219 and '094 patents, prior to the expiration of those patents, including any extensions to which Plaintiffs are or become entitled; and
- D. Plaintiffs be awarded such other and further relief as this Court deems just and proper.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Maryellen Noreika

Jack B. Blumenfeld (#1014)
Maryellen Noreika (#3208)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@mnat.com
mnoreika@mnat.com

*Attorneys for Plaintiffs
Helsinn Healthcare S.A. and
Roche Palo Alto LLC*

OF COUNSEL:

Joseph M. O'Malley, Jr.
Bruce M. Wexler
Eric W. Dittmann
David M. Conca
Gary Ji
Angela C. Ni
PAUL HASTINGS LLP
75 East 55th Street
New York, NY 10022
(212) 318-6000

*Attorneys for Plaintiff
Helsinn Healthcare S.A.*

Mark E. Waddell
LOEB & LOEB LLP
345 Park Avenue
New York, NY 10154
(212) 407-4127

*Attorneys for Plaintiff
Roche Palo Alto LLC*

July 11, 2014
8366032

CERTIFICATE OF SERVICE

I hereby certify that on July 11, 2014 I caused the foregoing to be electronically filed with the Clerk of the Court using CM/ECF, which will send notification of such filing to all registered participants.

I further certify that I caused copies of the foregoing document to be served on July 11, 2014 upon the following in the manner indicated:

Mary B. Matterer, Esquire
Richard K. Herrmann, Esquire
MORRIS JAMES LLP
500 Delaware Avenue, Suite 1500
Wilmington, DE 19801-1494
*Attorneys for Defendants Aurobindo Pharma Ltd.
and Auromedics Pharma LLC*

VIA ELECTRONIC MAIL

H. Keeto Sabharwal, Esquire
Nirav N. Desai, Esquire
Brett E. Howard, Esquire
Paul A. Ainsworth, Esquire
STERNE, KESSLER, GOLDSTEIN & FOX PLLC
1100 New York Avenue
Washington, DC 20005
*Attorneys for Defendants Aurobindo Pharma Ltd.
and Auromedics Pharma LLC*

VIA ELECTRONIC MAIL

Karen E. Keller, Esquire
David M. Fry, Esquire
SHAW KELLER LLP
300 Delaware Avenue, Suite 1120
Wilmington, DE 19801
*Attorneys for Defendant Ben Venue Laboratories,
Inc. d/b/a Bedford Laboratories*

VIA ELECTRONIC MAIL

Robert V. Cerwinski, Esquire
Huiya Wu, Esquire
Michael S. Chang, Esquire
KENYON & KENYON LLP
One Broadway
New York, NY 10004
*Attorneys for Defendant Ben Venue Laboratories,
Inc. d/b/a Bedford Laboratories*

VIA ELECTRONIC MAIL

William G. James, Esquire
KENYON & KENYON LLP
1500 K Street, NW
Washington, DC 20005
*Attorneys for Defendant Ben Venue Laboratories,
Inc. d/b/a Bedford Laboratories*

VIA ELECTRONIC MAIL

Adam W. Poff, Esquire
Monte T. Squire, Esquire
YOUNG CONAWAY STARGATT & TAYLOR, LLP
Rodney Square
1000 North King Street
Wilmington, DE 19801
Attorneys for Defendant Accord Healthcare, Inc.

VIA ELECTRONIC MAIL

Jill M. Browing, Esquire
P. Branko Pejic, Esquire
Paul A. Braier, Esquire
Neil F. Greenblum, Esquire
Michael J. Fink, Esquire
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
Attorneys for Defendant Accord Healthcare, Inc.

VIA ELECTRONIC MAIL

John C. Phillips, Jr., Esquire
Megan C. Haney, Esquire
David A. Bilson, Esquire
PHILLIPS GOLDMAN & SPENCE, P.A.
1200 North Broom Street
Wilmington, DE 19806-4204
*Attorneys for Defendants Cipla Ltd. and Cipla
USA, Inc.*

VIA ELECTRONIC MAIL

Robert F. Green, Esquire
Caryn C. Borg-Breen, Esquire
John P. Snow, Esquire
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, IL 60601-6731
*Attorneys for Defendants Cipla Ltd. and Cipla
USA, Inc.*

VIA ELECTRONIC MAIL

/s/ Maryellen Noreika

Maryellen Noreika (#3208)